SpringWorks Therapeutics Inc
NASDAQ:SWTX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
28.61
52.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
SpringWorks Therapeutics Inc
SpringWorks Therapeutics Inc
Total Other Income
SpringWorks Therapeutics Inc
Total Other Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Other Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SpringWorks Therapeutics Inc
NASDAQ:SWTX
|
Total Other Income
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Other Income
-$4.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Other Income
$302m
|
CAGR 3-Years
76%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Other Income
$578m
|
CAGR 3-Years
81%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Other Income
-$68m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Other Income
$6m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
8%
|
|
SpringWorks Therapeutics Inc
Glance View
SpringWorks Therapeutics Inc., a cutting-edge biopharmaceutical company, emerged from its inception as a strategic spin-out venture from the global pharmaceutical giant Pfizer. Born in 2017, the company cleverly positions itself at the forefront of the drug development process, with a keen focus on targeting rare diseases and cancer. SpringWorks leverages its robust pipeline of therapies, specifically designed to address significant unmet medical needs. Their approach revolves around the repurposing and reinvigoration of underappreciated and overlooked clinical molecules, which previously lacked the necessary backing to reach the market. This innovative approach allows SpringWorks to harness upstream R&D efforts while minimizing the typical time and resources required for de novo drug development. Earning its stripes in the field, SpringWorks generates revenue primarily through milestone and royalty agreements tied to its partnerships and co-development collaborations. Rather than relying solely on traditional sales of approved drugs, the company emphasizes strategic alliances with research institutions and pharmaceutical partners to advance its drug candidates. This co-development model extends its reach and augments the company's research capabilities, enabling SpringWorks to share risks and tap into broader resources. By nurturing innovations through collaboration, SpringWorks not only enriches its pipeline but also stands as a vanguard in transforming potential therapies into commercial realities, ultimately positioning itself as a linchpin in the orphan disease market.
You don't have any saved screeners yet
